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Seattle, Washington; Gaithersburg, Maryland; and Adelaide, AustraliaObjectives This study sought to describe near-infrared spectroscopy (NIRS) ﬁndings of culprit lesions
in ST-segment elevation myocardial infarction (STEMI).
Background Although autopsy studies demonstrate that most STEMI are caused by rupture of pre-
existing lipid core plaque (LCP), it has not been possible to identify LCP in vivo. A novel intracoronary
NIRS catheter has made it possible to detect LCP in patients.
Methods We performed NIRS within the culprit vessels of 20 patients with acute STEMI and compared
the STEMI culprit ﬁndings to ﬁndings in nonculprit segments of the artery and to ﬁndings in autopsy
control segments. Culprit and control segments were analyzed for the maximum lipid core burden
index in a 4-mm length of artery (maxLCBI4mm).
Results MaxLCBI4mm was 5.8-fold higher in STEMI culprit segments than in 87 nonculprit segments
of the STEMI culprit vessel (median [interquartile range (IQR)]: 523 [445 to 821] vs. 90 [6 to 265];
p < 0.001) and 87-fold higher than in 279 coronary autopsy segments free of large LCP by histology
(median [IQR]: 523 [445 to 821] vs. 6 [0 to 88]; p < 0.001).Within the STEMI culprit artery, NIRS
accurately distinguished culprit from nonculprit segments (receiver-operating characteristic analysis
area under the curve ¼ 0.90). A threshold of maxLCBI4mm >400 distinguished STEMI culprit segments
from specimens free of large LCP by histology (sensitivity: 85%, speciﬁcity: 98%).
Conclusions The present study has demonstrated in vivo that a maxLCBI4mm >400, as detected by
NIRS, is a signature of plaques causing STEMI. (J Am Coll Cardiol Intv 2013;6:838–46) ª 2013 by the
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839Each year in the United States alone, more than 1 million coronary intervention (PCI) at the Frederik Meijer Heart andAbbreviations
and Acronyms
AUC = area under the curve
IQR = interquartile range
IVUS = intravascular
ultrasound
LCBI = lipid core burden
index
LCP = lipid core plaque
MaxLCBI4mm = maximum
lipid core burden index
in 4 mm
NIRS = near-infrared
spectroscopy
PB = plaque burden
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarction
TIMI = Thrombolysis In
Myocardial Infarctionindividuals experience a myocardial infarction or sudden
cardiac death (1). These unexpected and often catastrophic
events occur despite a well-developed understanding of the
pathophysiology of the disorders (2–4). Post-mortemﬁndings
have proven thatmost cases of sudden coronary death and fatal
myocardial infarction are caused by rupture of a vulnerable
atherosclerotic plaque leading to occlusive thrombosis (2–8).
These autopsy studies have also demonstrated that the
underlying culprit lesion is frequently a large lipid core plaque
(LCP) (2,3,5–8).
In 1980, DeWood et al. (9) obtained data in vivo
demonstrating thrombus at the culprit site in patients expe-
riencing ST-segment elevation myocardial infarction
(STEMI). However, it has not been possible in living pa-
tients to accurately deﬁne the relationship between LCP and
STEMI culprit lesions. Identiﬁcation of LCP concentrated at
the site of thrombosis would be valuable because the LCP
may have been present prior to plaque rupture and throm-
bosis and could therefore have served as a target for preventive
therapy.
Intracoronary near-infrared spectroscopy (NIRS) has
recently been developed to identify LCP in patients un-
dergoing coronary angiography (10–15). NIRS has de-
monstrated that culprit lesions in stabilized patients with
non–ST-segment elevation acute coronary syndrome and in
patients with stable angina frequently contain LCP (15). In
the present study, the culprit lesion in STEMI patients was
evaluated with combined NIRS and intravascular ultrasound
(IVUS) imaging after restoration of arterial ﬂow, but before
alteration of the plaque by stenting. To assess the sensitivity
and speciﬁcity of the NIRS-IVUS ﬁndings, a case-control
analysis was performed in which the results obtained at
STEMI culprit sites were compared with those in nonculprit
portions of the STEMI culprit artery and in autopsy control
segments.
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approved by the Institutional Review Board of Spectrum
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Figure 1. Angiographic and NIRS Findings in Acute STEMI
(A) A patient 56 years of age with acute chest pain and inferior-posterior injury (a) was referred for primary PCI. Angiography of the right coronary artery revealed
complete occlusion (b). Aspiration yielded a thrombus characteristic of STEMI (c) and resulted in TIMI ﬂow grade 3 (d). NIRS performed after TIMI ﬂow grade 3 was
established revealed a prominent, nearly circumferential LCP concentrated at the culprit site (e). (B) Angiographic and NIRS ﬁndings in 8 patients with STEMI. In each
case, the initial angiogram demonstrated a culprit lesion (block arrow) with impaired ﬂow. Following treatment, TIMI ﬂow grade 3 is established. NIRS shows prominent
signs of LCP at culprit sites (asterisks denote culprit segment located between green lines), often in a circumferential pattern. LCP ¼ lipid core plaque; NIRS ¼ near-
infrared spectroscopy; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; TIMI ¼ Thrombolysis In Myocardial Infarction.
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841NIRS-IVUS imaging. NIRS-IVUS imaging (TVC Imaging
System, InfraReDx, Burlington, Massachusetts) was per-
formed after TIMI ﬂow grade 3 was established. The NIRS-
IVUS catheter was advanced beyond the culprit lesion and
motorized pullback was performed at 0.5 mm/s (18). After
NIRS-IVUS imaging, stents were placed in all but 1 patient
who was referred for bypass surgery for multivessel disease.
IVUS provided data useful for selection of optimal stent
diameter and length.
NIRS-IVUS analysis. NIRS images were interpreted as
previously described (10–15,18). For NIRS-IVUS analysis,
the STEMI culprit segment was deﬁned as the ﬁrst 10 mm
of artery distal to the proximal margin of the culprit lesion.
The vessel outside these margins was divided into non-
overlapping 10-mm nonculprit segments. To quantify the
amount of lipid present, we calculated the lipid core burden
index (LCBI), the fraction of pixels indicating lipid within a
region multiplied by 1,000 (10–15,18). Each 10-mm culprit
and nonculprit segment was scanned for the maximum
LCBI in any 4-mm region (maxLCBI4mm), as previously
described (10,14).
The NIRS-IVUS catheter provided coregistered IVUS
data for all NIRS imaging. IVUS analysis was performed
off-line by the Atherosclerosis Imaging Core Laboratory of
the Cleveland Clinic according to previously published meth-
odology and expert consensus recommendations (19–24).
IVUS parameters assessed included plaque burden (PB) and
calciﬁcation (Online Appendix).
Control groups. In the primary analysis, the ﬁndings in the
20 STEMI culprit segments were compared with ﬁndings in
all 87 nonculprit segments of the 20 culprit vessels. Addi-
tional comparisons were performed between STEMI culprit
segments and autopsy specimens selected for their LCP
ﬁndings on histologic analysis. Because prior autopsy studies
have demonstrated LCP to be present at STEMI culprit
sites (2–8), it was hypothesized that NIRS ﬁndings in
STEMI culprit segments would be similar to NIRS ﬁndings
in autopsy specimens with very large LCP by histology
(histology-positive, n ¼ 19) and differ from those in autopsy
specimens free of large LCP by histology (histology-negative,
n ¼ 279). We also compared NIRS ﬁndings within STEMI
culprit segments to NIRS ﬁndings in autopsy specimens from
individuals with no clinical history of coronary artery disease
(Online Appendix).
Statistical analysis. MaxLCBI4mm was the primary measure
of interest in this study. STEMI culprit segments were
compared to all nonoverlapping 10-mm segments in control
groups. Descriptive statistics were used to summarize
MaxLCBI4mm, PB, and the percentage of IVUS images
containing calcium. To test the ability of maxLCBI4mm, PB,
and calciﬁcation to differentiate STEMI culprit seg-
ments from nonculprit segments within the culprit artery,
receiver-operating characteristic analyses and calculations of
sensitivity, speciﬁcity, and positive and negative predictivevalues were performed. A similar analysis was performed to
determine the ability of maxLCBI4mm, PB, and calciﬁcation
to identify STEMI culprit segments when admixed with
histology-negative autopsy specimens. Logistic regression
modeling was used to determine the relative contribution of
each measure (maxLCBI4mm, PB, and calciﬁcation) to
identiﬁcation of culprit lesion status. Data analysis was
performed (by K.W.) at the Atherosclerosis Imaging Core
Laboratory of the Cleveland Clinic. Additional statistical
details are presented in the Online Appendix.
Results
Study population. Between January 20 and June 12, 2012,
NIRS-IVUS was performed within the culprit vessel of 23
patients experiencing STEMI. Of these, 1 patient was
excluded because the clinical presentation was attributable to
very late stent thrombosis and 2 patients were excluded
because of uninterpretable NIRS data. The analysis was
performed in the remaining 20 patients, all of whom had
a single culprit lesion identiﬁed by angiography (Online
Table 1). Culprit lesion location, initial TIMI ﬂow grades,
and methods used to establish TIMI ﬂow grade 3 prior to
NIRS-IVUS imaging are presented in Online Table 1.
NIRS ﬁndings in STEMI culprit lesions and control groups. As
shown in Figures 1 and 2, NIRS frequently identiﬁed
a large, nearly circumferential LCP at the STEMI culprit
site. The histologic basis of such large yellow spots on the
chemogram is demonstrated in Figure 3A. In Figure 3B,
chemograms from STEMI patients are compared to che-
mograms from the autopsy control groups.
Quantitative analysis revealed that maxLCBI4mm in
STEMI culprit segments (median [interquartile range
(IQR)]: 523 [445 to 821]) was 5.8-fold higher than in non-
culprit segments of the culprit vessel (median [IQR]: 90
[6 to 265]; p < 0.001) and 87-fold higher than in histology-
negative autopsy specimens (median [IQR]: 6 [0 to 88];
p < 0.001) (Fig. 4; Online Table 2). By receiver-operating
characteristic analysis, maxLCBI4mm identiﬁed STEMI
culprit segments accurately when admixed with nonculprit
segments of the culprit artery (area under the curve [AUC] ¼
0.90) and when admixed with histology-negative autopsy
specimens (AUC ¼ 0.97) (Fig. 5). A threshold of maxLC-
BI4mm >400 distinguished STEMI culprits from histology-
negative autopsy specimens with a sensitivity of 85% and
speciﬁcity of 98% (Online Table 3).
IVUS ﬁndings. STEMI culprit segments had a greater
PB and more frequent calciﬁcation than did nonculprit
segments in the culprit artery or histology-negative autopsy
specimens (Online Table 2). With respect to differentia-
ting culprit segments from nonculprit segments in the
STEMI culprit artery, maxLCBI4 mm performed similar to
PB (AUC: 0.90 vs. 0.86; p ¼ 0.44). Whereas both
maxLCBI4 mm and PB were able to identify STEMI culprits
Figure 2. NIRS Chemograms of STEMI Culprit Vessels
NIRS chemograms of all 20 STEMI patients (A). STEMI culprit segments (green arrows) contain LCP in 19 of 20 cases. The 1 case without yellow at the STEMI culprit
had a calciﬁed nodule by IVUS. Two IVUS cross sections within STEMI culprit segments show a large PB (B). IVUS ¼ intravascular ultrasound; PB ¼ plaque burden; other
abbreviations as in Figure 1.
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histology-negative autopsy specimens, the AUC for
maxLCBI4 mm was signiﬁcantly higher than that for PB
(0.97 vs. 0.83, p ¼ 0.015) (Fig. 5). MaxLCBI4mm was
signiﬁcantly more discriminatory at identifying STEMI
culprits than was calciﬁcation by IVUS when tested against
both control groups (Fig. 5). Although maxLCBI4mm, PB,
and calciﬁcation were all signiﬁcantly associated with
STEMI culprit segments by univariable analysis, maxLCBI4
mm emerged as the only signiﬁcant predictor by multivariable
analysis (Online Tables 4 and 5).
Discussion
The primary ﬁnding of the present study is the detection by
NIRS imaging of a signature of the culprit plaques causing
STEMI, a leading cause of death and disability throughout
the world (1). These novel in vivo ﬁndings are in accordance
with extensive ex vivo autopsy data (2–8), and they com-
plement in vivo observations documenting the presence of
thrombus at the culprit site in STEMI patients (9). Most
importantly for predictive and preventive purposes, it is
possible that the large LCP observed at STEMI culprit sites
were present and detectable before thrombus formation and
the acute coronary event.The ﬁnding of extensive LCP at STEMI culprit sites was
made possible by use of a novel NIRS-IVUS technology in
an acute setting. The NIRS system, developed speciﬁcally to
detect LCP within the coronary wall, has been extensively
validated in autopsy specimens and is cleared by the U.S.
Food and Drug Administration for this purpose (10,25).
Even though the NIRS system has been used in over 3,000
patients worldwide, the present study is the ﬁrst report of its
use in a consecutive series of STEMI patients with mini-
mally altered culprit plaques. The STEMI culprit lesion,
which is easily identiﬁed by the sudden occurrence of a focal,
occlusive thrombus, is particularly well suited as a standard
to detect a signature of a plaque prone to rupture and
thrombosis.
NIRS signature of STEMI culprit lesions. The present in vivo
ﬁndings are in agreement with multiple autopsy studies
documenting that rupture of a large LCP is the most
frequent cause of a fatal myocardial infarction (2–8). The
novel NIRS capability makes it possible to extend these
autopsy ﬁndings into patients undergoing stenting. A novel
observation in the present study, evident from visual exam-
ination of the STEMI culprit chemograms, is that the lipid
core at the culprit site is often circumferential in nature,
and sometimes quite narrowdfeatures captured by the
maxLCBI4mm measure. Our ﬁnding of circumferential LCP
Figure 3. NIRS Findings in STEMI Culprits and Autopsy Control Segments
(A) The relationship of yellow spots on the chemogram to histology. The top chemogram was obtained in a STEMI culprit vessel. The lower chemogram, obtained in
an autopsy specimen, shows 2 yellow spots similar to those observed in STEMI culprits. Histologic cross sections demonstrate both yellow spots on the lower
chemogram correspond with large lipid cores. (B) Chemograms in STEMI culprit vessels versus chemograms from autopsy control groups. NIRS evidence of LCP is
extensive in STEMI culprit segments (green arrow ¼ proximal angiographic culprit margin) and in histology-positive autopsy specimens. In contrast, NIRS evidence of
LCP is sparse in histology-negative autopsy specimens and in those with no clinical history of CAD. CAD ¼ coronary artery disease; other abbreviations as in Figure 1.
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843at many STEMI culprit sites is in accord with results of an
in vivo optical coherence tomography study (26), post-
mortem NIRS ﬁndings in a patient with sudden cardiacdeath (12), and with in vivo results obtained using other
intravascular imaging techniques that have reported evidence
of LCP at STEMI culprit sites (27–29).
Figure 4. MaxLCBI4mm in STEMI Culprit and Control Segments
MaxLCBI4mm for STEMI culprit segments (n ¼ 20), nonculprit segments of
the culprit vessel (n ¼ 87), and histology-negative autopsy control segments
(n ¼ 279). The blue box boundaries depict upper and lower bounds of
quartiles above and below the median (blue lines). The dashed red lines are
the means. MaxLCBI4mm in STEMI culprits was signiﬁcantly greater than in
either control group (p < 0.001). MaxLCBI4mm ¼ maximum lipid core burden
index in 4 mm; STEMI ¼ ST-segment elevation myocardial infarction.
Figure 5. ROC Analysis for Detection of STEMI Culprit Segments by NIRS
and IVUS
(A) The ability of NIRS and IVUS to distinguish culprit segments from non-
culprit segments in the STEMI culprit vessel. MaxLCBI4mm (red), PB (green),
and calciﬁcation (black) by IVUS are shown. MaxLCBI4mm was signiﬁcantly
more discriminatory than calciﬁcation (AUC: 0.90 vs. 0.72; p ¼ 0.016) and
performed similar to PB (AUC: 0.90 vs. 0.86; p ¼ 0.44). (B) The ability of NIRS
and IVUS to identify STEMI culprit segments when admixed with histology-
negative autopsy specimens. MaxLCBI4mm (red), PB (green), and calciﬁcation
(black) by IVUS are shown. MaxLCBI4mm was signiﬁcantly more discriminatory
at identifying STEMI culprit segments than were PB (AUC: 0.97 vs. 0.83; p ¼
0.015) or calciﬁcation (AUC: 0.97 vs. 0.79; p ¼ 0.002). PB and calciﬁcation were
not signiﬁcantly different (p ¼ 0.17). AUC ¼ area under curve; ROC ¼ receiver-
operating curve; other abbreviations as in Figures 1, 2, and 4.
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imaging studies, they differ in several important aspects.
First, previous studies with optical coherence tomography
(26) and virtual histology-IVUS (28) did not compare
culprit ﬁndings with control data for other sections of the
culprit artery. Second, although the angioscopy (29) and
grayscale-IVUS studies reported culprit artery control data,
the difference between ﬁndings for culprit and control lesion
was not as marked as for NIRS. Third, none of the previous
imaging studies (26–29) include ﬁndings in autopsy speci-
mens in which a histologic gold standard is available.
The control data for this study demonstrate that a
threshold maxLCBI4mm >400 has a 98% speciﬁcity for
identiﬁcation of STEMI culprit sites admixed with sites
from autopsy specimens free of large LCP. This high
speciﬁcity was achieved while maintaining a sensitivity of
85%. The 98% speciﬁcity applies to this cross-sectional
comparison of culprit sites with autopsy control lesions; the
speciﬁcity of the signature for prospective identiﬁcation of
lesions likely to cause a STEMI, or other coronary event, can
only be determined in a longitudinal prospective clinical
study. The single STEMI case that failed to show lipid at
the culprit site was found to have a calciﬁed noduleda
recognized infrequent cause of myocardial infarction (23).
MaxLCBI4mm also differed between the STEMI culprit
sites and nonculprit portions of the same vessel, indicating
the focal nature of coronary atherosclerotic lesions.
The ﬁnding of a NIRS signature at STEMI culprit sites
that differs signiﬁcantly from ﬁndings in control segments
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845contributes to the broader effort of detecting the signature of
a vulnerable plaque, deﬁned as a plaque prone to disruption
and thrombosis (30). The signature identiﬁed for STEMI
culprit lesions in the present study has also been observed in
other coronary conditionsdnon-STEMI, unstable angina,
and even stable angina (15,25). These observations are in
accord with the concept that rupture of a vulnerable plaque
may produce STEMI in some cases; sudden death, non-
STEMI, unstable angina, or stable angina in others; or may,
in a less obvious yet still harmful manner, simply contribute to
asymptomatic plaque progression (31). The ﬁnding by NIRS
of signiﬁcant amounts of LCP in non-STEMI, unstable
angina, and stable angina culprits supports the concept that
the STEMI culprit NIRS signature in a broader sense may be
considered the signature of a plaque prone to rupture (15).
IVUS features of STEMI culprit lesions. The ﬁndings of the
present cross-sectional study provide support for the con-
cept established by 2 recent prospective IVUS-based studies
that identiﬁcation of vulnerable plaques is possible. The
PROSPECT (Providing Regional Observations To Study
Predictors of Events in the Coronary Tree: An Imaging
Study in Patients With Unstable Atherosclerotic Lesions)
study identiﬁed PB >70% as the leading multivariable
predictor of subsequent coronary events (32). The
PREDICTION (Prediction of Progression of Coronary
Artery Disease Using Vascular Proﬁling of Shear Stress and
Wall Morphology) study conﬁrmed that baseline PB is
a predictor of lesion progression (33). Consistent with these
studies, we observed PB was signiﬁcantly increased at
STEMI culprit sites; however, multivariable analysis indi-
cated that PB was not needed to enhance the highly accu-
rate identiﬁcation of STEMI culprit sites provided by
NIRS alone. Furthermore, maxLCBI4mm is automatically
computer-generated for the segment analyzed and does not
require time-consuming analysis by an expert reader.
Implications for treatment. These data provide support for
the next step in evaluation of the NIRS signature of culprit
lesions, which is the conduct of a prospective prediction
study (34). If NIRS is prospectively validated as a reliable
predictor of clinical events, randomized studies of multiple
promising systemic and local therapies could be conducted.
The recent failure of several outcome studies of high-density
lipoprotein–raising therapy (35) demonstrates the need for
a more effective selection of agents to undergo such trials.
The YELLOW (Reduction in Yellow Plaque by Aggressive
Lipid Lowering Therapy) study (36) recently demonstrated
that NIRS could detect a reduction of coronary LCP with
high-dose rosuvastatin therapy. Promising agents such as the
PCSK9 inhibitors (37) and anti-inﬂammatory agents (4)
could be tested in a similar fashion.
Study limitations. First, the primary ﬁndings are based on
only 20 STEMI patients at a single center and only culprit
vessels were analyzed; however, the results are concordant
with previous pathologic data and large differences weredetected between STEMI culprit and control lesions.
Second, because maxLCBI4mm >400 as a threshold to
detect STEMI culprits was selected after examination of the
data, a prospective study using the threshold is needed.
Third, NIRS requires invasive study and is not suitable for
screening of the general population in which most coronary
events occur. For this reason, an initial clinical application of
NIRS could be for secondary prevention in those under-
going catheterization for other indications. If secondary
prevention could be demonstrated, primary prevention
strategies could be evaluated by using NIRS for invasive
conﬁrmation of plaques suspected to be vulnerable by
noninvasive testing (38,39). Fourth, the majority of STEMI
culprit lesions were in the right coronary artery; it is
unknown if the present ﬁndings would be altered in a
population with predominantly left coronary artery
culprits. Finally, culprit lesion PB may have been reduced by
spontaneous embolization of friable plaque contents after
plaque rupture or by balloon angioplasty before imaging.
Conclusions
A NIRS signature of the plaques causing STEMI has been
detected in vivo. This signature accurately detects STEMI
culprit lesions admixed with nonculprit segments of the
culprit vessel or with segments from autopsy control lesions.
These data support conduct of a long-term, large prospective
study to test the hypothesis that intracoronary NIRS can
provide accurate, site-speciﬁc prediction that a given plaque
is likely to cause a coronary event and thereby facilitate
development of more effective preventive therapies.
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